Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain (IMPROVE)

Boston Scientific

Status: Enrolling

Conditions: Chronic Low-back Pain; Vertebrogenic Pain Syndrome

Treatments: Device: Intracept™ Intraosseous Nerve Ablation

Study type: Observational

Funder types: Industry

Identifiers

NCT06827262

REL025

Details and patient eligibility

About

Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

Full description

The objective of this study is to compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

Enrollment: 1,500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU).
• Signed a valid, IRB/EC-approved informed consent form.

Exclusion criteria

• Meets any contraindications per locally applicable Instructions for Use (IFU).

Trial design

1,500 participants in 1 patient group

Intracept™ Intraosseous Nerve Ablation Systems

Description:

Subjects with pain treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System

Treatment:

Device: Intracept™ Intraosseous Nerve Ablation